Tarbox Family Office’s Blueprint Medicines BPMC Stock Holding History

Tarbox Family Office’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-13	Closed	-$1K	–	1081
2021 Q4	$1K	Hold	13	–	–	﹤0.01%	979
2021 Q3	$1K	Hold	13	–	–	﹤0.01%	1021
2021 Q2	$1K	Hold	13	–	–	﹤0.01%	1026
2021 Q1	$1K	Hold	13	–	–	﹤0.01%	997
2020 Q4	$1K	Hold	13	–	–	﹤0.01%	965
2020 Q3	$1K	Hold	13	–	–	﹤0.01%	927
2020 Q2	$1K	Hold	13	–	–	﹤0.01%	917
2020 Q1	$1K	Buy	+13	New	+$837	﹤0.01%	802

Other funds holding BPMC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Tarbox Family Office's BPMC Position: Q1 2022 in Review

Tarbox Family Office sold out of Blueprint Medicines (BPMC) in Q1 2022, closing a stake of 13 shares — an estimated $1K sold.

Tarbox Family Office first reported a position in BPMC in Q1 2020 and held it in 8 quarters. The position peaked at $1K in Q4 2021. 248 funds tracked by Wall St. Rank hold BPMC as of Q1 2022.

Tarbox Family Office reported no remaining Blueprint Medicines position as of Q1 2022 after selling out during the quarter.
Tarbox Family Office sold 13 Blueprint Medicines shares in Q1 2022, an estimated $1K.
Tarbox Family Office first reported a position in Blueprint Medicines in Q1 2020 and held it in 8 quarters.
Tarbox Family Office's Blueprint Medicines position peaked at $1K in Q4 2021.
248 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2022.

Based on Tarbox Family Office's 13F filing for Q1 2022, filed 25 Apr 2022.